This trial is testing whether a year of treatment with the drug enzalutamide can help treat early stage triple negative breast cancer that is positive for the androgen receptor.
1 Primary · 0 Secondary · Reporting Duration: 3 years
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: Enzalutamide · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: